Peptides for Injury Recovery: What the Research Shows

Injury Recovery Research

Peptides for injury recovery have their clearest human data in BPC-157 and thymosin beta-4, the repair protein TB-500 is derived from: in a 2021 clinic review, 14 of 16 knee-pain patients reported relief after BPC-157, and in a 2015 phase 2 trial, thymosin beta-4 eye drops cut ocular discomfort by 35.1% against a placebo solution. GHK-Cu adds a placebo-controlled wound trial, and KPV adds anti-inflammatory laboratory research. Each is summarised below, with links to the full write-ups and the Repair & Recovery stacks.

View product →

Findings

• BPC-157, knee: in a 2021 retrospective review at a Florida primary-care clinic, 14 of 16 patients (87.5%) reported relief of knee pain, including 11 of 12 given BPC-157 alone.
• BPC-157, bladder: in a 2024 pilot, 10 of 12 women with interstitial cystitis reported complete resolution of symptoms after a single procedure, and the other two rated their success at 80%.
• Thymosin beta-4, eye: in severe dry eye, 35.1% less discomfort and 59.1% less corneal staining than the placebo solution at day 56 (Cornea, 2015).
• Thymosin beta-4, skin: in a 73-patient phase 2 venous ulcer trial, about 25% of patients reached complete wound closure within three months (2010).
• GHK-Cu: in diabetic foot ulcers, median ulcer closure of 98.5% against 60.8% on vehicle, and infections in 7% against 34% (Wound Repair Regen, 1994).

Which peptides have human repair data?

Peptide	Study	Result
BPC-157	16 knee-pain patients (2021)	14 of 16 reported relief
BPC-157	12 women, bladder pain (2024)	10 of 12 complete resolution
Thymosin beta-4	9 with severe dry eye (2015)	Discomfort down 35.1% vs placebo
Thymosin beta-4	73 with venous ulcers (2010)	About 25% closed in 3 months
GHK-Cu	Diabetic foot ulcers (1994)	Median closure 98.5% vs 60.8%

What has BPC-157 research shown for injury recovery?

BPC-157 is a synthetic 15-amino-acid peptide derived from gastric proteins. A 2025 systematic review of 36 studies found that, in early-stage laboratory research, it improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury models (HSS J). The three human reports share a first author:

• 2021, knee pain. A retrospective chart review at a primary-care clinic in Orlando followed up 16 patients who had BPC-157 given into the knee joint for several types of knee pain. Eleven of 12 given BPC-157 alone reported significant improvement, as did 3 of 4 who also received thymosin beta-4: 14 of 16, or 87.5%, overall. The full study is in BPC-157 and TB-500 for knee pain.
• 2024, bladder pain. Twelve women aged 39 to 76 with moderate to severe interstitial cystitis, none of whom had responded to the approved drug pentosan polysulfate, received BPC-157 around the inflamed area of the bladder during a single cystoscopy. Ten reported complete resolution and rated their success at 100%, the other two rated it at 80%, and there were no dropouts or adverse events. More in BPC-157 for bladder pain and interstitial cystitis.
• 2025, safety. Two adults received intravenous BPC-157 on consecutive days with no measurable effect on heart, liver, kidney, thyroid or blood glucose markers, and no side effects reported.

A 2026 review with pain-medicine authors from Johns Hopkins describes these three pilots as pointing to potential value, with no major adverse effects reported. BPC-157 comes as a lyophilised vial and as the ready-mixed BPC-157 Nasal Spray (10 mg in 5 mL).

Sources: Yuan C et al. Int J Mol Sci. 2026. PMID 41898733. Vasireddi N et al. HSS J. 2025. PMID 40756949. Lee E, Padgett B. Altern Ther Health Med. 2021. PMID 34324435. Lee E, Walker C, Ayadi B. Altern Ther Health Med. 2024. PMID 39325560. Lee E, Burgess K. Altern Ther Health Med. 2025. PMID 40131143.

What did the thymosin beta-4 trials find?

TB-500 is a synthetic peptide derived from thymosin beta-4, a naturally occurring 43-amino-acid repair protein that platelets release at the site of an injury. Thymosin beta-4 itself has phase 2 trial data:

• Severe dry eye, 2015. In a randomised, double-masked, placebo-controlled trial in nine patients, eyes given thymosin beta-4 drops had 35.1% less ocular discomfort and 59.1% less corneal staining than the placebo solution at day 56, four weeks after the drops stopped (Cornea).
• Dry eye, 72 people, 2015. Discomfort during a controlled adverse environment challenge was 27% lower than placebo at day 28, and central and superior corneal staining improved, with no adverse events; the primary endpoints at day 29 did not differ significantly (Clin Ophthalmol).
• Corneal defects, 2010. Nine patients aged 37 to 84 with chronic neurotrophic corneal defects used thymosin beta-4 eye drops on a compassionate basis. The six with geographic defects showed dramatic repair, and all reported less irritation soon after starting.
• Venous ulcers, 2010. A double-blind, placebo-controlled phase 2 trial randomised 73 patients at eight sites in Italy and Poland. Safety was comparable to placebo, and the authors report complete wound closure within three months in about 25% of patients, especially those with small to moderate wounds. A 2012 review of this and a pressure ulcer trial reports that wounds which closed did so almost a month sooner.

In early-stage laboratory research, thymosin beta-4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7, with more collagen deposition and new blood vessel growth (J Invest Dermatol, 1999). TB-500 comes as a vial and as the TB-500 Nasal Spray (10 mg in 5 mL); the trial record is in TB-500 and thymosin beta-4: the repair research.

Sources: Sosne G, Dunn SP, Kim C. Cornea. 2015. PMID 25826322. Sosne G, Ousler GW. Clin Ophthalmol. 2015. PMID 26056426. Dunn SP et al. Ann N Y Acad Sci. 2010. PMID 20536469. Guarnera G et al. Ann N Y Acad Sci. 2010. PMID 20536470. Treadwell T et al. Ann N Y Acad Sci. 2012. PMID 23050815. Malinda KM et al. J Invest Dermatol. 1999. PMID 10469335.

Why are BPC-157 and TB-500 combined?

Their research covers different parts of repair. BPC-157’s laboratory profile centres on new blood vessel growth, collagen synthesis and fibroblast activity; thymosin beta-4’s on cell migration, new blood vessels and damping inflammation. The knee review is the one human report of the pairing, with 3 of 4 patients given both reporting significant improvement. The BPC-157 + TB-500 vial combines them, and the BPC-157 + TB-500 Nasal Spray holds 10 mg of each in 10 mL. The Wolverine Stack (also called the Healing Blend) covers the pairing in depth.

Where do GHK-Cu, GLOW and KLOW fit?

GHK-Cu is a copper-binding tripeptide first isolated from human plasma. In a multicentre, randomised, evaluator-blinded, placebo-controlled trial in diabetic neuropathic foot ulcers, a GHK-Cu gel used alongside standard wound care raised median ulcer closure to 98.5% against 60.8% on vehicle (p < 0.05) and closed ulcers three times faster. In larger ulcers, median closure was 89.2% against minus 10.3%, and when the gel was started right after debridement, infections fell to 7% against 34% (Wound Repair Regen, 1994). In early-stage laboratory research, GHK-Cu stimulated collagen synthesis by fibroblasts, peaking at one nanomolar (FEBS Lett, 1988).

The GLOW Blend combines 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in one vial, and the KLOW Blend adds 10 mg KPV. Both also come ready-mixed as the GLOW Nasal Spray and KLOW Nasal Spray. KLOW vs GLOW explains the choice.

Sources: Mulder GD et al. Wound Repair Regen. 1994. PMID 17147644. Maquart FX et al. FEBS Lett. 1988. PMID 3169264.

What has KPV research shown on inflammation?

KPV (Lys-Pro-Val) is the last three amino acids of alpha-MSH. A 2008 review describes it as keeping the parent hormone’s anti-inflammatory activity without its effect on pigment, and lists inflammatory skin and bowel disease, fibrosis and arthritis among its research directions (Endocr Rev). In human intestinal and immune cells, nanomolar KPV inhibited the NF-kB and MAP kinase inflammatory pathways and lowered pro-inflammatory cytokine secretion, and given orally it reduced inflammation in two colitis models (Gastroenterology, 2008). The published work to date is early-stage laboratory research. KPV comes as a vial and as the KPV Nasal Spray.

Sources: Brzoska T et al. Endocr Rev. 2008. PMID 18612139. Dalmasso G et al. Gastroenterology. 2008. PMID 18061177.

The Repair & Recovery stacks, sprays and vials

The Repair & Recovery stack pairs the BPC-157 + TB-500 vial with KPV. The Repair & Recovery Spray Stack does the same ready-mixed: the BPC-157 + TB-500 Nasal Spray (20 mg in 10 mL) and the KPV Nasal Spray (10 mg in 5 mL), in sterile saline with metered pumps. Vials are reconstituted with bacteriostatic water (the peptide calculator does the arithmetic). Orders ship from within Canada by Canada Post Xpresspost, with certificates of analysis on the lab reports page.

Frequently asked questions

What has BPC-157 research shown for injury recovery?

In a 2021 clinic review, 14 of 16 knee-pain patients (87.5%) reported relief after BPC-157. In a 2024 pilot, 10 of 12 women with interstitial cystitis reported complete resolution after one procedure. A 2025 systematic review found improved outcomes in muscle, tendon, ligament and bone injury models.

What has thymosin beta-4 (TB-500) research shown in humans?

Thymosin beta-4, the protein TB-500 is derived from, has phase 2 trials. Its eye drops cut ocular discomfort by 35.1% and corneal staining by 59.1% against a placebo solution in severe dry eye (2015), and in a 73-patient venous ulcer trial, about 25% of patients reached complete closure within three months (2010).

What has GHK-Cu research shown on wound repair?

In a placebo-controlled trial in diabetic foot ulcers, a GHK-Cu gel raised median ulcer closure to 98.5% against 60.8% on vehicle, closed ulcers three times faster, and cut infections to 7% against 34% when started right after debridement (1994).

What has KPV research shown?

KPV, the last three amino acids of alpha-MSH, keeps the hormone’s anti-inflammatory activity without its pigment effect. In human intestinal and immune cells it damped the NF-kB inflammatory pathway at nanomolar concentrations (2008).

Where can I buy BPC-157 and TB-500 in Canada?

Vistara Labs supplies BPC-157, TB-500 and the BPC-157 + TB-500 blend as vials and ready-mixed nasal sprays, plus GHK-Cu, KPV, GLOW, KLOW and both Repair & Recovery stacks, shipped from within Canada by Canada Post Xpresspost.

Shoulder and back. The animal research on BPC-157 and TB-500 in rotator cuff, spinal cord and nerve injury is summarised in BPC-157 and TB-500 for shoulder and back pain.

More on this: Peptides for Skin: What the Research Shows.

References

No controlled human trial of the BPC-157 + TB-500 combination was identified. In the retrospective knee-pain review below, four patients received BPC-157 with full-length thymosin β4 — a different molecule from TB-500.

1. Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee E et al. · Altern Ther Health Med 2021 · PMID 34324435Retrospective chart review, 17 patients (16 followed up by telephone); no control group, no blinding, no validated outcome instrument.
2. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potentialEsposito S et al. · Drug Test Anal 2012 · PMID 22962027Analytical chemistry: characterises TB-500 as the N-terminally acetylated 17-23 fragment of thymosin β4 (Ac-LKKTETQ), not the intact 43-amino-acid protein.
3. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewVasireddi N et al. · HSS J 2025 · PMID 40756949Systematic review; 544 records screened, 36 studies included — 35 preclinical and 1 clinical.

Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.